Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 5—May 2004

Beijing/W Mycobacterium tuberculosis in Italy

Cite This Article

To the Editor: Molecular typing of Mycobacterium tuberculosis strains isolated in several countries in recent years has shown that a group of strains known as “Beijing” is widespread around the world (1). The Beijing group of M. tuberculosis has been associated with drug resistance; one multidrug-resistant strain, designated “W,” was found in New York City in the early 1990s and caused large institutional outbreaks of tuberculosis (TB) in the United States (2). M. tuberculosis strains of Beijing/W genotype are mostly prevalent in Asia (1), but recent data suggest that they have been spreading in Indochina and are prevalent among younger persons in Vietnam (3). Beijing/W strains are also widespread in Eastern Europe (1); during the last decade, the Beijing/W genotype of M. tuberculosis, with more prevalent drug-resistant mutations than non-Beijing strains, has been identified in 40% to 50% of clinical isolates studied in Russia (4).

We studied a total of 245 M. tuberculosis strains collected during a 1-year period, from January to December 2002, from the same number of TB patients hospitalized in Tuscany, Italy. All the isolates were typed by the standardized IS6110 restriction fragment length polymorphism (RFLP) and the spoligotyping (spacer oligonucleotide typing) techniques. A total of 216 distinct IS6110 RFLP patterns were found among the 245 isolates; 51 isolates (20.8%) occurred in 23 clusters, each constituting strains with an identical IS6110 RFLP and spoligotype pattern; 19 clusters contained two isolates each, 3 contained three isolates, and 1 contained four isolates. Spoligotype analysis showed seven isolates with the typical Beijing/W pattern of probe hybridization only to spacer sequences 35–43. The Beijing/W isolates yielded distinct IS6110 RFLP profiles with similarity coefficient >57.8%. Characteristics of the Beijing/W strains and respective patients, obtained from clinical records, are reported in the Table. Although the overall prevalence of Beijing/W strains was low (7/245, 2.9%), five of the seven strains were from recent immigrants to Italy from China who live in the same area; the other two strains were from Italian citizens also living in that area. Recent immigration from high-prevalence areas is therefore likely to be associated with the occurrence of the Beijing/W genotype in Italy. None of the Beijing/W strains was associated with TB outbreaks; nonetheless, infection of Italian residents with Beijing strains suggests that spread of this genotype is ongoing.

Beijing/W strains have been strongly associated with drug resistance in a number of countries (2,46), but elsewhere the association was weak or absent. In our survey, no substantial drug resistance was observed; all Beijing/W strains isolated in Tuscany were susceptible to rifampin, ethambutol, pirazinamide, and streptomycin (tested only in two strains), and all but one were susceptible to isoniazid.

Although we detected only a few cases, our data do not show a trend of Beijing/W strains’ being associated with infection in young people, as has been observed in other settings (3). The age of immigrants with Beijing/W TB (mean 33.2 years, standard deviation [SD] 8.2 years) did not significantly differ from that of immigrants infected with non-Beijing/W strains (30.7 years, SD 7.4 years), a find that indicates that, at least in our setting, immigrant status, rather than M. tuberculosis genotype, is associated with infection in young people. The few cases of Beijing/W infections in Italian-born patients do not allow us to draw conclusions regarding nonimmigrant patients.

In conclusion, M. tuberculosis strains of Beijing/W genotype are becoming widespread worldwide, including in countries with a low prevalence of TB. Their association with drug resistance and infection in young people, clearly shown in certain settings, remains to be defined. Further molecular epidemiologic surveillance is needed to monitor trends in prevalence and spread of these strains.



This work was supported by National Research Program on AIDS grant no. 50D.11 from the Istituto Superiore di Sanità, Rome, Italy.


Nicoletta Lari*, Laura Rindi*, Daniela Bonanni*, Enrico Tortoli†, and Carlo Garzelli*Comments to Author 
Author affiliations: *Università di Pisa, Pisa, Italy; †Ospedale Careggi, Firenze, Italy



  1. Glynn  JR, Whiteley  J, Bifani  PJ, Kremer  K, van Soolingen  D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis. 2002;8:8439.PubMedGoogle Scholar
  2. Bifani  PJ, Mathema  B, Liu  Z, Moghazeh  SL, Shopsin  B, Tempalski  B, Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology. JAMA. 1999;282:23217. DOIPubMedGoogle Scholar
  3. Anh  DD, Borgdorff  MW, Van  LN, Lan  NT, van Gorkom  T, Kremer  K, Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis. 2000;6:3025. DOIPubMedGoogle Scholar
  4. Mokrousov  I, Otten  T, Vyazovaya  A, Limeschenko  E, Filipenko  ML, Sola  C, PCR-based methodology for detecting multidrug-resistant strains of Mycobacterium tuberculosis Beijing family circulating in Russia. Eur J Clin Microbiol Infect Dis. 2003;22:3428. DOIPubMedGoogle Scholar
  5. Diaz  R, Kremer  K, de Haas  PE, Gomez  RI, Marrero  A, Valdivia  JA, Molecular epidemiology of tuberculosis in Cuba outside of Havana, July 1994–June 1995: utility of spoligotyping versus IS6110 restriction fragment length polymorphism. Int J Tuberc Lung Dis. 1998;2:74350.PubMedGoogle Scholar
  6. Kruuner  A, Hoffner  SE, Sillastu  H, Danilovits  M, Levina  K, Svenson  SB, Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol. 2001;39:333945. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid1005.031024

Related Links


Table of Contents – Volume 10, Number 5—May 2004


Please use the form below to submit correspondence to the authors or contact them at the following address:

C. Garzelli, Dipartimento di Patologia Sperimentale, Biotecnologie Mediche, Infettivologia ed Epidemiologia, Università di Pisa, Via San Zeno, 35/39, I-56127 Pisa, Italy; fax: +39-050-2213671

Send To

10000 character(s) remaining.


Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.